Bedrijfsoverzicht
Fractyl Health, Inc. is a metabolic therapeutics company dedicated to developing novel therapies for the treatment of type 2 diabetes and obesity, with a specific focus on the Revita DMR System designed as an outpatient procedural therapy to durably modify duodenal dysfunction. The company operates within the Healthcare sector, specifically the Biotechnology industry, a classification that typically implies high research and development costs, long product development cycles, and a reliance on intellectual property rather than immediate cash generation from established product lines. The firm currently maintains a market capitalization of $72.98 million, employs approximately 100 individuals, and reports no available annual revenue figures in the trailing twelve months. These valuation metrics and operational scale indicators suggest that Fractyl Health is a mid-to-small cap biotechnology entity operating in a capital-intensive environment where the primary value driver is the potential future success of its proprietary therapeutic candidates rather than current profitability or established sales volume.
Financiële gezondheid
The company's financial statements reflect a pre-revenue or early-stage commercialization status, with revenue reported as N/A for the trailing twelve months, while the net income stands at a significant loss of $-140,954,000 and EBITDA at $-95,687,000. The substantial gap between the reported revenue (which is unavailable) and the heavy net loss reveals a cost structure dominated by research, development, and administrative expenses typical of a company in the clinical trial or pre-market approval phase where no sales revenue is being generated to offset operational burn. Free cash flow is reported at $-56,585,000, indicating that the company is consuming cash reserves to fund its operations and development pipeline, which limits immediate financial flexibility and necessitates ongoing access to capital markets or private funding. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that in the context of biotechnology often reflects the absence of commercial sales data required to calculate these percentages rather than a negative profitability ratio, signaling that traditional margin analysis is not yet applicable. Regarding liquidity and leverage, the company holds $81.54 million in cash against $61.65 million in debt, resulting in a debt-to-equity ratio of 651.79 which highlights a highly leveraged balance sheet relative to its equity base, though the absolute debt level is manageable given the cash position. The current ratio is reported at 4.78, indicating strong short-term liquidity relative to current liabilities, suggesting the company can comfortably meet its immediate obligations despite the lack of operating income. Furthermore, the return on equity is -744.2% and the return on assets is -52.7%, metrics that mathematically reflect the heavy losses and high debt levels relative to the equity base, revealing that management effectiveness is currently measured by the preservation of cash rather than the generation of returns on capital.
Waarderingsbeoordeling
Valuation multiples for Fractyl Health present a complex picture typical of loss-making biotechnology firms, with the trailing twelve-month P/E ratio listed as N/A due to the lack of positive net income and the forward P/E standing at -0.81, which mathematically implies that future earnings are still negative and do not yet support a traditional price-to-earnings valuation based on profitability. The price-to-book ratio is calculated at 7.42, indicating that the market values the company at a significant premium over its net asset book value, a scenario often driven by the potential value of intangible assets such as patents and clinical data rather than tangible assets. Alternative valuation metrics further illustrate this disparity, with the price-to-sales ratio unavailable due to the lack of revenue data and the EV/EBITDA ratio at -0.56, suggesting that investors are pricing the stock based on future catalysts rather than current earnings power or sales multiples. In terms of price volatility and trading range, the stock has a 52-week high of $3.03 and a 52-week low of $0.38, meaning the current price sits within a wide historical band where the upper limit represents a 694.7% gain over the lower limit, highlighting the speculative nature of the investment. The beta is recorded at 1.19, which indicates that the stock's price volatility is approximately 19% higher than the broader market, suggesting that the company's share price is more sensitive to market fluctuations than large-cap, stable equities.
Growth & Income
Growth metrics for Fractyl Health are currently unavailable, with both revenue growth year-over-year and earnings growth year-over-year reported as N/A due to the company's lack of commercial revenue and negative earnings history. Consequently, it is not possible to calculate whether earnings are growing faster or slower than revenue as no positive base exists for comparison, implying that the company is in a stage of business development where growth is measured by clinical progress rather than financial expansion. Regarding income distribution, the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that the firm reinvests all available capital and retained earnings directly into its research and development efforts rather than distributing income to shareholders. The overall growth and income profile for Fractyl Health is characterized by a complete absence of current financial returns or dividends, positioning the asset as a pure play on the future success of its metabolic therapy pipeline with no current cash return for investors.